Results 71 to 80 of about 7,021 (220)
Treatment of facioscapulohumeral muscular dystrophy with Denosumab [PDF]
American Journal of Case Reports, 2012 Facioscapulohumeral muscular dystrophy (FSHD) is the 3(rd) most common form of muscular dystrophy. Effective treatments for any of the muscular dystrophies have yet to be realized. This report describes such a treatment.A 66 year old female was diagnosed with osteoporosis. She had been diagnosed with FSHD muscular dystrophy a number of years previously
Doris L. Lefkowitz +2 more
openaire +3 more sources
Disability, Subject‐Dependence, and the Bad‐Difference View
Bioethics, Volume 39, Issue 9, Page 802-809, November 2025.ABSTRACT Philosophers have debated on the “mere‐difference” view of disability, according to which disability as such is neutral in terms of well‐being, just like race and gender. It is contrasted with the “bad‐difference” view, which holds that disability is bad for its possessor even in a non‐ableist situation.
Shu Ishida +2 more
wiley +1 more source
Assessment of the Use of Non-Pharmacological Methods for Managing Depression in Patients with Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD) [PDF]
, 2018 Background: Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are two types of muscular dystrophies with multi-system manifestations.
Miller, Kimberly +3 more
core +1 more source
The FASEB Journal, Volume 39, Issue 19, 15 October 2025.ERRα promotes muscle regeneration. ERRα drives angiogenic and mitochondrial metabolic gene program in proliferating and differentiating myogenic cells. ERRα also induces myogenic factor genes such as MyoG. Through these pathways ERRα promotes muscle regeneration in the skeletal muscle in acute injury and chronic myopathy.
Thi Thu Hao Nguyen +8 more
wiley +1 more source
Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model
Nature Communications, 2017 Facioscapulohumeral muscular dystrophy is a severe myopathy that is caused by abnormal activation of DUX4, and for which a suitable mouse model does not exist.
Darko Bosnakovski +7 more
doaj +1 more source
Facioscapulohumeral muscular dystrophy [PDF]
Current Opinion in Neurology, 2012 In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental ...
Maarel, S.M. van der +4 more
openaire +4 more sources
Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy
Trends in Molecular Medicine, 2021 Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common types of muscular dystrophy, affecting roughly one in 8000 individuals. The complex underlying genetics and poor mechanistic understanding has caused a bottleneck in therapeutic development.
Angela Lek +3 more
openaire +4 more sources
Facial paresis as the first sign in atypical facioscapulohumeral muscular dystrophy
Otolaryngology Case Reports, 2022 Background: Facioscapulohumeral muscular dystrophy (FSHD) is the one of the most common types of muscular dystrophy. We present a retrospective case description of a patient with late-onset, atypical FSHD and provide an overview of the clinical history ...
Nneoma S. Wamkpah, John J. Chi
doaj +1 more source
Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry [PDF]
, 2016 Facioscapulohumeral dystrophy (FSHD) is a rare inherited neuromuscular disease estimated to affect 1/15,000 people. Through basic research, remarkable progress has been made towards the development of targeted therapies.
Evangelista, T +13 more
core +1 more source
Molecular Therapy: Methods & Clinical Development, 2018 RNAi emerged as a prospective molecular therapy nearly 15 years ago. Since then, two major RNAi platforms have been under development: oligonucleotides and gene therapy.
Lindsay M. Wallace +10 more
doaj +1 more source